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ABSTRACT
Introduction: Association studies between single nucleotide polymorphisms (SNPs) and type 2 diabetes mellitus 
(T2DM) have been abundant.  However, there are limited reports on copy number variations (CNVs) of beta-defen-
sins (DEFB) gene in relation to T2DM. In this study, DEFB copy numbers were quantified in T2DM with nephropathy, 
T2DM without nephropathy and non-diabetic control groups to investigate its influence in chronic inflammation in 
Malaysian individuals. Methods: DEFB copy number in Malaysian individuals were quantified by using paralogue 
ratio tests (PRT) which allow direct quantification of gene copy number by using PRT107A and HSPD21 PRT primers. 
The copy number generated was then validated from insertion/deletion ratio measurement 5DEL (rs5889219) and 
two microsatellite analyses (EPEV-1 and EPEV-3). Results: DEFB copy number was found extending from 2 to 8 cop-
ies in the non-diabetic group (n=146), while in T2DM group (n=392), copy numbers were more extensive, ranging 
between 1 and 12 copies; with 1, 10 and 12 copies detected in T2DM with nephropathy group (n=202). Statistically, 
there is no significant difference in DEFB copy number between T2DM and the non-diabetic group (p=0.209) as 
well as between diabetic nephropathy and without nephropathy of the T2DM group (p=0.522). However, significant 
white blood cell (WBC) count was found between T2DM groups with and without diabetic nephropathy (p=0.000). 
Conclusion: Extreme DEFB copy numbers in T2DM with nephropathy group suggest future studies with bigger sam-
ple size are necessary to elucidate the true impact of CNVs of DEFB gene in promoting early onset of nephropathy 
in T2DM.
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INTRODUCTION
Diabetes mellitus affects 422 million adults globally 
in 2014, compared to 108 million in 1980, causing 
prevalent morbidity and mortality cases in middle- and 
low-income countries (1). In Malaysia, the prevalence 
of type 2 diabetes mellitus (T2DM) showed alarming 
increase from 11.6% in 2006 to 15.2% in 2011 and 
further escalates to 17.5% in 2015 which involved 3.5 
million adult population of 18 years and above (2). 
Moreover, 40-60% of T2DM individuals in Malaysia 
developed diabetic nephropathy (DN) which may 
progress into end-stage renal disease (ESRD) and leading 
to death (3). 
Numerous studies have been conducted to investigate 
the role of genetic variants in increasing individual’s risk 
of T2DM. Significant evidence suggested strong genetic 
influence underlies this this multifactorial disease as 
monozygotic twins shares 96% concordance rate for 
genetic contribution towards T2DM (4). The advancement 
in technology enable genome-wide association scans 
(GWAS) which confirmed nine loci (PPARG, KCNJ11, 
TCF7L2, CDKAL1, CDKN2A/B, IGF2BP2, HHEX/IDE, 
FTO and SLC30A8) with susceptibility towards T2DM 
from the aspect of single nucleotide polymorphisms 
(SNPs) (4). However, recent studies suggest that common 
variants also have compelling effect on pathophysiology 
of the disease, apart from the rare variants which could 
only be found in certain individuals or populations (4). 
As (GWAS) catered for large-scale genotyping, there 
is limited knowledge on the true potential of common 
variants involving copy number variations (CNVs) in 
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disease and complications prediction. (4, 17).
The role of beta-defensins in inflammatory conditions 
has been described in previous studies. Defensins 
are small, cationic, cytotoxic, antimicrobial and 
immunoregulatory peptides that function as the innate 
defence mechanism by inducing production of pro-
inflammatory cytokines and activation of complement 
systems (5). Beta-defensins exhibit copy number 
variations (CNVs) which commonly ranging between 
2 and 7 copies in healthy Caucasian population (6) 
and has been associated with susceptibility towards 
inflammatory conditions including psoriasis (7), Crohn’s 
disease (8, 9), HIV (10), adenocarcinoma (11) as well 
chronic obstructive pulmonary disease (COPD) (12) 
through alteration of gene dosage.  
Nevertheless, accurate copy number quantification of 
DEFB is technically demanding due to the complex and 
extensive duplication of DEFB gene (13, 14). Therefore, 
paralogue ratio test (PRT) was used in this study as a 
mean of robust and accurate copy number quantification 
of the multiallelic DEFB (15, 16) which overcame the 
limitations reported for several measurement techniques, 
including quantitative real-time PCR (qPCR) (14).
As most studies on CNVs of DEFB investigated complex 
diseases, efforts in unveiling the association with 
common diseases are still needed. Thus, it is important to 
further characterize this variant especially in Malaysian 
population, which has not been genotyped before. In 
this study, we aimed to quantify CNVs in DEFB gene by 
using PRT system validation by indel and microsatellite 
analysis to ensure final copy number were inferred 
with high confidence. At the same time, the role of 
CNVs in T2DM and diabetic nephropathy were further 
elucidated.
MATERIALS AND METHODS
Ethical Approval and Subjects Recruitment
The study protocol obtained approval from Ministry 
of Health Malaysia (NMRR 13-1614-16772). Informed 
consent was obtained from all study subjects. A total 
of 146 non-diabetic controls were recruited at health 
check-up centre Hospital Tuanku Jaafar and Universiti 
Putra Malaysia (UPM) were comprised of 51 Malay, 53 
Chinese and 42 Indian individuals. On the other hand, 
T2DM individuals were recruited from Hospital Tuanku 
Jaafar, Seremban, Negeri Sembilan were consist of 137 
Malay, 124 Chinese and 131 Indian individuals. Out of 
392 T2DM samples, 202 individuals have been diagnosed 
with diabetic nephropathy while 190 individuals were 
free of it at the time of sample collection. All subjects 
enrolled in this study are Malaysian and includes both 
male and female (Table I). 
DEFB copy number from Human Random Control 
(HRC) DNA Panel 1 and 2 from European Collection 
of Authenticated Cell Cultures (ECACC) samples of 
Caucasian origin were directly used as the copy number 
were known from previous typing (14, 16). In this 
study, the copy number was used to construct copy 
number distribution for Caucasian population. At the 
same time, several samples were selected as internal 
control (reference samples) to infer copy number for 
the unknown samples by deriving a linear regression 
equation from each PRT systems (7, 16).
Genomic DNA extraction
QIAamp DNA Mini Kit (QIAGEN, Germany) was used to 
extract DNA from 200 uL of peripheral blood collected 
in BD Vacutainer® K2 EDTA tubes according to 
manufacturer’s protocol. The concentration and purity of 
the extracted DNA were quantified by using Nanodrop 
ND-1000 spectrophotometer (Thermo Scientific, USA).  
Paralogue ratio test (PRT) systems
Paralogue ratio test (PRT) is a robust technique designed 
to reliably genotype multiallelic CNVs using small 
quantity of genomic DNA in large sample size (7, 15). 
In order to determine DEFB copy number, PRT systems 
were carried out as described by Aldhous et al. (14) and 
Abu Bakar et al. (16) which can simultaneously amplify 
the test and reference loci in a single PCR reaction. Since 
one of the PRT primer (either forward or reverse) were 
fluorescently-label, it enables the test and reference 
amplicons to be separated by capillary electrophoresis, 
generating peaks of the amplified PCR products. The 
peak heights and values were then compared for copy 
number determination (7, 15). Due to the nature of DEFB 
gene cluster (consisting of seven genes), the segmental 
duplication (SD) that span this region theoretically 
means that each DEFB-specific gene exists in same 
number of copies. Therefore, 2 PRT primers (PRT107A 
and HSPD21) were previously designed to measure 
gene copy number at specific DEFB gene (DEFB107 and 
DEFB4) at each end of the DEFB repeat unit to ensure 
precise copy number quantification for each sample 
(14, 16).
Table I Distribution of T2DM and non-diabetic control samples based 
on gender and age
Number (Age range, years)
T2DM with 
nephropathy
T2DM without 
nephropathy
Non-diabetic 
controls
Female
Malay 27(45-84) 22 (47-70) 25 (23-41)
Chinese 33 (37-83) 31 (36-83) 26 (23-35)
Indian 37 (45-75) 28 (45-86) 21 (22-50)
Male
Malay 46 (46-80) 41 (44-78) 26 (23-47)
Chinese 27 (42-86) 33 (48-89) 27 (24-41)
Indian 32 (47-76) 33 (46-82) 21 (24-55)
Total 202 188 146
N = 536
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PRT107A amplifies a test locus downstream of DEFB107 
on chromosome 8 and its reference paralogue on 
chromosome 11, whereas HSPD21 amplified a target 
locus upstream of DEFB4 and its reference paralogue 
on chromosome 21 (14, 16). The test and reference 
paralogues were determined using PRT primer design 
tool (PRTPrimer, University of Leicester). The test and 
reference paralogues shared similar sequences but only 
to differ by a single nucleotide change and the reference 
paralogue should not map on a copy-variable region to 
ensure relative comparison of copy number between 
paralogues can be obtained in a single amplification 
reaction (7, 15).
The PRT primers were fluorescently labelled: FAM/
HEX for PRT107A and FAM/TAMRA for HSPD21, to 
allow duplication as well as aiding in calibration of the 
experiment. Multiplex PCR was conducted by preparing 
a total of 10 uL reaction mixture consisting of 1 uL (10 ng) 
DNA, 5 uL of 2X Prime Taq Premix (Genet Bio, Korea), 
0.5 ul (10 uM) of each of forward and reverse primers 
for PRT107A and HSPD21 and 2 uL of double-distilled 
water (ddH2O). DNA samples were amplified in a pre-
denaturation step at 95°C for 5 minutes and followed by 
repeated cycles of denaturation at 95°C for 30 seconds, 
annealing at 58°C for 30 seconds and extension at 70°C 
for 1 minute for 25 cycles.  This cycle was followed by 
another annealing step at 58°C for 30 seconds and final 
extension at 70°C for 40 minutes. 
5DEL (rs5889219) system
An indel known as 5DEL (rs5889219) was adapted (14, 
16) to validate integer copy number quantified by PRT 
systems. DNA samples were amplified in 28 cycles of 
denaturation at 95°C for 30 seconds, annealing at 58°C 
for 30 seconds and extension at 70°C for 1 minute, 
followed by another annealing step at 58°C for 1 min 
and final extension at 70°C for 20 minutes. A single PCR 
reaction was prepared in a total of 10 uL of 1 uL (10 ng) 
DNA, 5 uL of 2X Prime Taq Premix (Genet Bio, Korea), 
0.5 ul (10 uM) of each of forward and reverse 5DEL 
primers and 3 uL of ddH2O.
Triplex assay
Amplification by both PRT systems was carried out in a 
duplex PCR reaction, while 5DEL was run in a separate 
reaction. In a Triplex assay, amplification products 
from PRT107A, HSPD21 and 5DEL were combined. 
1 µl of each PCR products was taken from each plate 
and mixed with ROX marker and HiDi formamide in a 
separate 96-well plate before being resolved by capillary 
electrophoresis. Amplification by PRT107A resulted in 
amplicons sized at 155 bp (chromosome 11) and 157 
bp (chromosome 8) while HSPD21’s amplicons sized 
at 180 bp (chromosome 21) and 172 bp (chromosome 
8). Peak heights and values from 155 bp and 157 bp 
and 180 bp and 172 bp, were compared respectively 
for each PRT primer. Mean ratio from dual fluorescent 
for each PRT primer were used during the analysis. A 
total of four HRC DNA samples were used to calibrate 
each experiment resulting in linear regression to infer 
DEFB copy number from this assay. On the other hand, 
amplification by 5DEL resulted in amplicons sizing 
at 125, 128 and 130 bp length. The genomic ratio of 
each peaks to the smallest peak were taken resulting in 
estimated copy number (Fig. 1).
Figure 1:  Electropherogram as recorded by Peak ScannerTM 
for a 4-copy sample typed by Triplex assay. Test and reference 
peaks for PRT systems for FAM-labelled products are shown 
by arrows. For HEX–labelled 5DEL system, ratio of each peak to the 
smallest peak (1:1) was taken and multiplied by a factor of 2 to reflect 
copy number of 4 as typed by PRT systems.  
Microsatellite analysis
Two sets of primers; EPEV-1 (6) and EPEV-3 (16) were 
used to amplify the microsatellite alleles. The inferred 
copy number from Triplex assay and microsatellite 
analysis were analysed based on the single system 
analysis. Both primers were fluorescently labelled with 
HEX to perform the capillary electrophoresis. DNA was 
amplified in 25 cycles of denaturation at 95°C for 1 
minute, annealing at 58°C for 1 minute and extension 
at 72°C for 1 minute was carried out. 1 µl of each PCR 
products was taken from each plate and mixed with 
ROX marker and HiDi formamide before being resolved 
in capillary electrophoresis. EPEV-1 yielded alleles 
of different lengths ranging between 171 bp – 193 bp 
while alleles from EPEV-3 amplification ranged between 
133 bp – 147 bp. The peak height ratios of all alleles 
to the smallest allele were taken and total allelic ratio 
resulted in integer copy number which further used to 
validate inferred copy number from PRT systems. The 
primer sequences used in this study are listed in Table II.
Statistical analysis
In this study, student’s t-test were used to compare 
DEFB mean copy number for four assessments: 1) 
between HRC ECACC (Caucasian) and non-diabetic 
control (Malaysian), 2) between non-diabetic control 
and T2DM groups, 3) between T2DM with and without 
nephropathy and 4) between male and female groups. 
Next, one-way ANOVA was used to compare mean copy 
number among the three major ethnicities of Malaysian 
individuals for both control and T2DM groups. In 
addition, the relationship between DEFB copy number 
and white blood cell (WBC) count T2DM group was 
tested by using Pearson correlation.
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Based on our findings, there was more individuals with 
>4 copies (31.5%) than <4 copies (23.5%) of DEFB 
gene. As this is the first study in Malaysia which involved 
typing of the multiallelic DEFB gene copy number, 
the distribution obtained was compared to a different 
population to check if differences exist in distribution of 
DEFB copy number. Therefore, the copy number of the 
non-diabetic group was compared to ECACC samples 
(an established copy of Caucasian healthy population) 
which was readily available from previous typing and 
has been published (14, 16). Distribution of DEFB copy 
number was compared in a histogram to assess the 
extent of copy number in healthy groups from different 
populations. Based on our analysis, both groups 
(European Caucasian; 2 to 9 copies) and non-diabetic 
control (Malaysian; 2 to 8 copies) shared similar pattern 
of distribution with similar modal copy number of 4 
(p=0.377, t-test) (Fig. 3).
We also analysed the comparison among the ethnicities 
to investigate if different ethnicities may have different 
distribution pattern. Based on our findings, the copy 
number distribution among the three major ethnicities 
from Malaysian non-diabetic control samples shared a 
Table II Primer sequences for DEFB copy number quantification.
Validation Primer 
name
Sequences
Paralogue ratio test 
(PRT)
PRT107A FAM- or HEX-labelled forward: 
5’-AGCCTCATTTAACTTTGGTGC-3’
Reverse:
5’-GGCTATGAAGCAATGGCCTA-3’
HSPD21 Forward:
5’-GAGGTCACTGTGATCAAAGAT-3’
FAM- or TAMRA- labelled reverse:
5’-AACCTTCAGCACAGCTACTC-3’
Indel 5DEL HEX- or TAMRA- labelled forward: 
5’-AAACCAATACCCTTTCCAAG-3’
Reverse:
5’-TTCTCTTTTGTTTCAGATTCAGATG-3’
Microsatellite anal-
ysis
EPEV-1 HEX-labelled forward: 
5’-GGCAGTATTCCAGGATACGG-3’
Reverse:
5’-GAACAATTAGATATCCCTATGC-3’
EPEV-3 HEX-labelled forward:
5’-GATACTGTGAACTACAGATCAC-3’
Reverse:
5’-CTGCCCTGATTCAGTATTGAAC-3’
RESULTS
Typing analysis of DEFB copy number in non-diabetic 
control group
DEFB copy number were successfully typed in a total 
of 146 non-diabetic control. The copy number for non-
diabetic controls were first established in this study prior 
to T2DM and diabetic nephropathy to compare the 
distribution between both groups. By using single system 
analysis, 71% (104/146) samples was recorded for 
measurement of unrounded copy number by PRT107A 
and HSPD21 in non-diabetic control group with 29% of 
the samples were rejected due to the stringent criteria 
in PRT measurement. A linear adjustment was applied 
to PRT107A measurement due to the shifting involving 
PRT107A measurement which were also reported in 
previous studies (14, 16). The unrounded copy number 
were compared in a histogram (Fig. 2A). A mean copy 
number of 4.19 was observed in a subset of 104 non-
diabetic samples. The unrounded copy number was 
transformed to the closest integer which caused a 
substantial difference in frequency for copy number 2, 
3, 4, 6 and 7 between both PRTs recorded with 58.65% 
concordance rate (Fig. 2B). Quantification by 5DEL and 
microsatellites were carried out to carefully analyse the 
peak traces in all 146 non-diabetic samples inclusive 
of the rejected samples from PRT system measurement. 
Thus, a distribution of copy number for a total of 146 
non-diabetics produced a distribution between 2 and 8 
copies with a modal diplotype of 4 recorded in the non-
diabetic group (Fig. 2C). 
Figure 2:  Copy number distribution in non-diabetic control 
group. A) Histogram of unrounded copy number showed copy number 
measurement yielded by both PRT systems through comparison of test 
and reference amplification products. B) Histogram of integer copy 
number using both systems were obtained when the unrounded copy 
number were rounded. Both measurements agreed at modal copy 
number of 4, with overestimation depicted by PRT107A measurement. 
C) Distribution of final copy number was obtained after validation of 
PRT systems with 5DEL and microsatellite analysis. 
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modal copy number of 4. Despite the increased mean 
copy number in Chinese (4.19) compared to Indian 
(4.14) and Malay (4.08), there is no significant difference 
in mean copy number distribution among ethnics from 
the non-diabetic population (p=0.878, ANOVA). Our 
analysis on copy number distribution on gender factor 
also showed that male have higher mean copy number 
(4.23) than female (4.04), yet no significant difference 
was observed (p=0.303, t-test). 
Typing analysis of DEFB copy number distribution in 
T2DM group 
DEFB copy number were quantified in 392 T2DM 
samples which was further divided based on their 
nephropathy status (202 with nephropathy, 188 
without nephropathy and 2 samples with unknown 
nephropathy status). Unrounded copy number by 
PRT107A and HSPD21 was successfully produced in 
90.8% (356/392) T2DM samples using PRT systems 
with 9.18% rejections after the criteria have been 
applied. Histogram of unrounded copy number by both 
PRT systems demonstrated clusters for copy number 
3, 4, 5 and 6 regardless of the loose clustering pattern 
which caused overlapping between copy number 4, 5 
and 6. Besides that, the distribution of copy number was 
widely disseminated involving samples with higher copy 
number. However, an overestimation by 1.5 copies 
was recorded in PRT107A after linear adjustment was 
applied compared to HSPD21 for copy number 2 and 3, 
while loose cluster pattern remained for copy number 6 
and above (Fig. 4A). 
PRT measurement showed that T2DM groups shared 
similar copy number of 4 with mean copy number of 4.38 
in 356 T2DM individuals with 38.52% concordance 
(Fig. 4B). Similar approach was applied on T2DM 
cohort by validating PRT-inferred copy number from 
356 samples as a part of Triplex assay. Through careful 
analysis, a subset of 53 samples required clarification 
by microsatellite analysis to confirm final copy number. 
In addition, 36 samples which had been previously 
removed during PRT measurement were included again 
and the peak traces from the electrophoresis were 
carefully analysed. Hence, a distribution of copy number 
for a total of 392 T2DM individuals was produced in 
Malaysian individuals, showing that DEFB copy number 
varies extensively between 1 and 12 copies with a 
modal copy number of 4 (Fig. 4C).  
There were more individuals with >4 copies (36.2%) 
than <4 copies (25.2%) of DEFB gene. Nevertheless, 
copy number distribution between non-diabetic controls 
and T2DM were not significantly different in integer 
(p=0.209, t-test) copy number measurement (Fig. 5A). 
Although there is an increased mean unrounded copy 
number observed in Malay (4.46), followed by Indian 
(4.21) and Chinese (4.18), there was no significant 
difference in mean copy number distribution observed 
among these ethnicities from T2DM group (p=0.132, 
ANOVA). Likewise, male with T2DM showed increased 
mean copy number (4.31) than female (4.26). Yet, there 
was no significant difference observed (p=0.740, t-test).
We also found a more extreme variation between 1 
and 12 copies in T2DM with nephropathy compared 
to 2 and 9 copies in T2DM group without nephropathy 
(Fig. 5B). Individuals with nephropathy showed a 
Figure 3: Histograms of integer copy number between ECACC 
(European Caucasian) and non-diabetic (Malaysian) control 
groups. This step is taken to validate the distribution of DEFB copy 
number as the first typing made in Malaysian control population.
Figure 4:  Copy number distribution in T2DM group. A) 
Histogram of unrounded copy number showed copy number 
measurement yielded by both PRT systems through comparison of test 
and reference amplification products. B) Histogram of integer copy 
number using both systems were obtained when the unrounded copy 
number were rounded. Both measurements agreed at modal copy 
number of 4. Again, overestimation of 4 copies can be observed in 
PRT107A measurement. C) Distribution of final copy number was 
obtained after validation of PRT systems with 5DEL and microsatellite 
analysis. 
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higher white blood cell (WBC) count and mean copy 
number (10.204x109 cell/L; mean copy number 4.33) 
compared to those without nephropathic complications 
(8.487x109 cells/L, mean copy number 4.24). However, 
the mean copy number does not significantly differ 
between these two groups (P=0.522, t-test) and there 
was no correlation found between WBC count and copy 
number among T2DM individuals (r=0.047, p=0.367) 
despite the significant increase in mean WBC count in 
individuals with diabetic nephropathy (p=0.000, t-test). 
SNP array to detect CNV in Singapore population of 
Malay, Chinese and Indian (17). However, the range 
of copy number generated from Malaysian population 
show consistency with UK’s British population even 
though the distance between these countries is 10,576 
km apart. It is still unclear whether the similar pattern 
is due to heterogeneous sampling of combining Malay, 
Chinese and Indian or due to the small sample size (18). 
Meanwhile, our typing showed an extreme variation 
in T2DM samples which is considerably different than 
the non-diabetic individuals, yet not significant enough. 
From our observation, the number of T2DM individuals 
having >4 copies of DEFB is higher than those having 
<4 which may hint that high copy number of DEFB 
might predispose our population to T2DM which is also 
increasing every year. Mean copy number is also higher 
in individuals with diabetic nephropathy compared to 
those without. Therefore, this is consistent with previous 
findings of high copy number in chronic inflammatory 
diseases as seen in psoriasis (7), systemic lupus 
erythematosus (SLE) and antineutrophil cytoplasmic 
antibodies (ANCA)-associated small vasculitis (19), 
higher HIV load (10) and acne inversa (20). There is also 
evidence of inducible human beta-defensins 2 (HBD-
2) gene expression in chronic bacterial infection which 
is absent in normal kidney condition (21) which may 
highlight the unfamiliar role of DEFB in inflamed kidney 
tissues. 
The signal transduction of white blood cell for recruitment 
towards inflammatory sites is heavily influenced by 
HBD antimicrobial peptide which modulate secretion of 
cytokines (5). Based on this principle, we hypothesized 
that DEFB copy number might be correlated with WBC 
count screened from T2DM individuals. However, 
there was no correlation between WBC and DEFB copy 
number found, despite the significant increase of WBC 
count in nephropathic individuals. For future studies, 
quantification of HBD2 concentration is necessary to 
study the correlation with DEFB copy number as well 
as WBC count. 
Based on the study that have been conducted, there are 
several limitations that were encountered. Firstly, the 
small sample size for non-diabetic populations may not 
be able to truly represent the Malaysian population. As 
the copy number of DEFB copy is already extensively 
variable, inclusion of more samples might be able to 
reflect the true genetic makeup by including not only 
the major ethnicities, but also the minorities, including 
the aborigines. Bigger sample size may increase possible 
inclusion of the less encountered individuals with high 
copy numbers.
Secondly, the establishment of non-diabetic sample 
was made by comparison against the Caucasian sample 
as there is a lack of complete reference copy number 
available from another heterozygous population. 
However, the study proceeded considering that both 
Figure 5:  Histogram of integer copy number involving 
T2DM group. A) Copy number distribution in non-diabetic control 
and T2DM group, and B) in T2DM group with and without diabetic 
nephropathy (DN). Note that the copy number is more extensive in 
T2DM group, particularly the group with DN with extremely low copy 
number (1 copy, denoting deletion in one of the gene copy) and high 
copy numbers (10 and 12 copies).
DISCUSSION
Current understanding highlights the importance of 
DEFB copy number influence in inflammatory diseases. 
However, there are limited studies conducted to explore 
its influence in T2DM as well as diabetic nephropathy 
as most studies were revolving around alpha-defensins 
(DEFA) CNV which has established association with the 
kidney. Apart from that, we are also hampered by the 
limited references in Asian populations, particularly on 
Malaysian population. 
In this study, we quantified DEFB copy number from 
genomic DNA extracted from peripheral blood to 
investigate DEFB copy number distribution in both non-
diabetic and T2DM Malaysian individuals. By using a 
combination of Triplex assay and microsatellite analyses, 
a careful analysis was conducted to carefully assign the 
copy numbers, yielding a distribution of 2 to 8 copies in 
the non-diabetic samples. Thus, our results support the 
previously detected beta-defensins CNV loci through 
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populations were typed using similar PRT method.
Thirdly, there is a gap in direct correlation between 
DEFB CNV and HBD2 which was not assessed in this 
study. We would recommend further investigations into 
HBD2 dosage through common techniques such as 
enzyme-linked immunosorbent assay (ELISA) or a gene 
expression study to judge the level of functional mRNA, 
in relation to DEFB CNV. 
CONCLUSION
From this study, PRT has once again proven to be a robust 
and simple method in accurate quantification involving 
complex, multiallelic and extensive copy number as 
seen in DEFB gene for huge sample size. The precise 
quantification is convincing to develop it as one of the 
diagnostic tools in targeting risk factors for T2DM and 
diabetic nephropathy. Hence, intervention measures 
can be taken in high risk populations. As we study the 
DEFB gene, we also see that there is a possibility that 
HBD can be a biomarker of inflammation, which can 
be a channel towards specific treatment in controlling 
the chronic inflammation, not only in T2DM, but also 
in other inflammatory disorders. Although there was 
no significant association was established between 
DEFB CNV and T2DM from this study, extreme DEFB 
copy numbers found in T2DM with nephropathy group 
suggest that future studies with bigger sample size are 
necessary to elucidate the true impact of CNVs of DEFB 
gene in promoting early onset of nephropathy in T2DM.
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